Trial Profile
TheraP: A Randomised Phase 2 Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (ANZUP Protocol 1603)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary) ; Cabazitaxel
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms TheraP
- 01 Aug 2023 Results published in the Journal of Nuclear Medicine
- 06 Jun 2023 Results assessing effect of [177Lu] Lu-PSMA-617 on overall survival in TheraP versus VISION trials presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 14 Oct 2022 Results published in the Lancet Oncology